STAG2 mutations reshape the cohesin-structured spatial chromatin architecture to drive gene regulation in acute myeloid leukemia.

CP: Cancer CP: Molecular biology Hi-C RAD21 STAG2 acute myeloid leukemia cohesin mutations epigenetics gene regulation hematopoiesis hematopoietic stem and progenitor cells spatial chromatin structure

Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
25 Jul 2024
Historique:
received: 11 12 2023
revised: 24 05 2024
accepted: 27 06 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 31 7 2024
Statut: aheadofprint

Résumé

Cohesin shapes the chromatin architecture, including enhancer-promoter interactions. Its components, especially STAG2, but not its paralog STAG1, are frequently mutated in myeloid malignancies. To elucidate the underlying mechanisms of leukemogenesis, we comprehensively characterized genetic, transcriptional, and chromatin conformational changes in acute myeloid leukemia (AML) patient samples. Specific loci displayed altered cohesin occupancy, gene expression, and local chromatin activation, which were not compensated by the remaining STAG1-cohesin. These changes could be linked to disrupted spatial chromatin looping in cohesin-mutated AMLs. Complementary depletion of STAG2 or STAG1 in primary human hematopoietic progenitors (HSPCs) revealed effects resembling STAG2-mutant AML-specific changes following STAG2 knockdown, not invoked by the depletion of STAG1. STAG2-deficient HSPCs displayed impaired differentiation capacity and maintained HSPC-like gene expression. This work establishes STAG2 as a key regulator of chromatin contacts, gene expression, and differentiation in the hematopoietic system and identifies candidate target genes that may be implicated in human leukemogenesis.

Identifiants

pubmed: 39084219
pii: S2211-1247(24)00827-1
doi: 10.1016/j.celrep.2024.114498
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114498

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Alexander Fischer (A)

Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany; Leibniz Institute for Immunotherapy, Regensburg, Germany.

Benjamín Hernández-Rodríguez (B)

Regulatory Genomics, Max Plank Institute for Molecular Medicine, Münster, Germany.

Roger Mulet-Lazaro (R)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

Margit Nuetzel (M)

Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

Fabian Hölzl (F)

Leibniz Institute for Immunotherapy, Regensburg, Germany.

Stanley van Herk (S)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

François G Kavelaars (FG)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Hanna Stanewsky (H)

Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

Ute Ackermann (U)

Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.

Amadou H Niang (AH)

Regulatory Genomics, Max Plank Institute for Molecular Medicine, Münster, Germany.

Noelia Diaz (N)

Regulatory Genomics, Max Plank Institute for Molecular Medicine, Münster, Germany.

Edith Reuschel (E)

Department of Obstetrics and Gynecology, Hospital St. Hedwig of the Order of St. John, Regensburg, Germany.

Nicholas Strieder (N)

Leibniz Institute for Immunotherapy, Regensburg, Germany.

Inmaculada Hernández-López (I)

Leibniz Institute for Immunotherapy, Regensburg, Germany.

Peter J M Valk (PJM)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Juan M Vaquerizas (JM)

Regulatory Genomics, Max Plank Institute for Molecular Medicine, Münster, Germany; Department of Developmental Epigenomics, MRC London Institute of Medical Sciences, London, UK; Institute of Clinical Sciences, Imperial College London, London, UK.

Michael Rehli (M)

Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany; Leibniz Institute for Immunotherapy, Regensburg, Germany.

Ruud Delwel (R)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

Claudia Gebhard (C)

Leibniz Institute for Immunotherapy, Regensburg, Germany. Electronic address: claudia.gebhard@klinik.uni-regensburg.de.

Classifications MeSH